ArticleNature communications2025
Developing an alternative medium for in-space biomanufacturing.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Collagen-heparan sulfate microcarriers support mesenchymal stem cell culture in microgravity and streamline post-flight recovery.NPJ microgravity · 2026Article
- Elucidating biodegradation of dimethyl terephthalate by twoMetabolic engineering communications · 2026Article
- Orbital biomanufacturing: the key to space resiliency, operational persistence, and ethical sustainability.NPJ microgravity · 2026Review
- Anabaena-a promising chassis for space exploration.NPJ microgravity · 2026Review
- Microgravity-induced constraints on melanin bioproduction: investigating E. coli metabolic responses aboard the international space station.NPJ microgravity · 2026Article
- Emerging Chemical and Biological Materials Technologies in the Extraplanetary Environment.Nano-micro letters · 2026Review
- Multicriteria evaluation of ethylene glycol assimilation pathways.Journal of industrial microbiology & biotechnology · 2026Article
- Applications of bio-enhanced cementitious composites for sustainable building materials: emission-reduction and carbon-sequestration pathways.Systems microbiology and biomanufacturing · 2026Review
- Cryogenic microcarrier-assisted stem cell storage (Cryo-MASCS): a preservation method enabling scalable culture of human mesenchymal stem cells.Stem cell research & therapy · 2025Article
- Be a GEM: Biocontained, environmentally applied, genetically engineered microbes.Advanced drug delivery reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
In-space biomanufacturing provides a sustainable solution to facilitate long-term, self-sufficient human habitation in extraterrestrial environments. However, its dependence on Earth-supplied feedstocks renders in-space biomanufacturing economically nonviable. Here, we develop a process termed alternative feedstock-driven in-situ biomanufacturing (AF-ISM) to alleviate dependence on Earth-based resupply of feedstocks. Specifically, we investigate three alternative feedstocks (AF)-Martian and Lunar regolith, post-consumer polyethylene terephthalate, and fecal waste-to develop an alternative medium for lycopene production using Rhodococcus jostii PET strain S6 (RPET S6). Our results show that RPET S6 could directly utilize regolith simulant particles as mineral replacements, while the addition of anaerobically pretreated fecal waste synergistically supported its cell growth. Additionally, lycopene production using AF under microgravity conditions achieved levels comparable to those on Earth. Furthermore, an economic analysis shows significant lycopene production cost reductions using AF-ISM versus conventional methods. Overall, this work highlights the viability of AF-ISM for in-space biomanufacturing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.